Literature DB >> 9402096

Evaluation of pathologic criteria for acute renal allograft rejection: reproducibility, sensitivity, and clinical correlation.

R B Colvin1, A H Cohen, C Saiontz, S Bonsib, M Buick, B Burke, S Carter, T Cavallo, M Haas, A Lindblad, J C Manivel, C C Nast, D Salomon, C Weaver, M Weiss.   

Abstract

This study was designed to evaluate the pathologic criteria used for acute renal allograft rejection that were developed by a panel of renal pathologists participating in the Cooperative Clinical Trials in Transplantation, a National Institutes of Health-supported, multicenter research group. The panel defined three categories of acute rejection. (1) Type I: mononuclear infiltrate in > or =5% of cortex, a total of at least three tubules with tubulitis in 10 consecutive high-power fields from the most severely affected areas, and at least two of the three following features: edema, activated lymphocytes, or tubular injury. (2) Type II: arterial, or arteriolar, endothelialitis with or without the preceding features. (3) Type III: arterial fibrinoid necrosis or transmural inflammation with or without thrombosis, parenchymal necrosis, or hemorrhage. Using these criteria, and without any knowledge of the clinical course or original diagnosis, a rotating panel of three pathologists agreed with the original study pathologist's diagnosis of the presence or absence of rejection in 259 of the 286 biopsies (91%) used for this analysis (kappa = 0.80). The sensitivity to establish the diagnosis of rejection was 91% for a single core and 99% for two cores. To validate the diagnostic criteria, the thresholds for number of tubules with tubulitis and the percent infiltrate were varied, and the pathologic diagnosis was compared with the clinical course. The greatest agreement occurred with a threshold of > or =1 tubule with tubulitis and > or =5% cortex with interstitial infiltrate (91%). Clinically severe rejection episodes were correlated with the type of rejection (type I, odds ratio [OR] 6.2; type II, OR 37.9). Type II rejection was more likely to be clinically severe than type I (OR 6.1). Analysis of other individual pathologic features revealed a correlation with clinical severity for endothelialitis (OR 13.2), interstitial hemorrhage (OR 13.2), and the presence of glomerulitis (OR 3.7) (all P < 0.05). The extent of tubulitis or of the interstitial infiltrate did not correlate with severity (P > 0.05). It is concluded that these criteria are simple, reproducible, and clinically relevant. These data should lead to further refinement of the diagnostic systems for renal allograft rejection.

Entities:  

Mesh:

Year:  1997        PMID: 9402096     DOI: 10.1681/ASN.V8121930

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  31 in total

1.  Aspergillus antigen testing in bone marrow transplant recipients.

Authors:  E C Williamson; D A Oliver; E M Johnson; A B Foot; D I Marks; D W Warnock
Journal:  J Clin Pathol       Date:  2000-05       Impact factor: 3.411

2.  A molecular classifier for predicting future graft loss in late kidney transplant biopsies.

Authors:  Gunilla Einecke; Jeff Reeve; Banu Sis; Michael Mengel; Luis Hidalgo; Konrad S Famulski; Arthur Matas; Bert Kasiske; Bruce Kaplan; Philip F Halloran
Journal:  J Clin Invest       Date:  2010-05-24       Impact factor: 14.808

3.  Discovery and validation of a molecular signature for the noninvasive diagnosis of human renal allograft fibrosis.

Authors:  Dany Anglicheau; Thangamani Muthukumar; Aurélie Hummel; Ruchuang Ding; Vijay K Sharma; Darshana Dadhania; Surya V Seshan; Joseph E Schwartz; Manikkam Suthanthiran
Journal:  Transplantation       Date:  2012-06-15       Impact factor: 4.939

Review 4.  Histopathological diagnosis of acute and chronic rejection in pediatric kidney transplantation.

Authors:  Verena Bröcker; Michael Mengel
Journal:  Pediatr Nephrol       Date:  2013-10-19       Impact factor: 3.714

5.  Blocking MHC class II on human endothelium mitigates acute rejection.

Authors:  Parwiz Abrahimi; Lingfeng Qin; William G Chang; Alfred L M Bothwell; George Tellides; W Mark Saltzman; Jordan S Pober
Journal:  JCI Insight       Date:  2016-01-21

6.  The Banff Working Group Classification of Definitive Polyomavirus Nephropathy: Morphologic Definitions and Clinical Correlations.

Authors:  Volker Nickeleit; Harsharan K Singh; Parmjeet Randhawa; Cinthia B Drachenberg; Ramneesh Bhatnagar; Erika Bracamonte; Anthony Chang; W James Chon; Darshana Dadhania; Vicki G Davis; Helmut Hopfer; Michael J Mihatsch; John C Papadimitriou; Stefan Schaub; Michael B Stokes; Mohammad F Tungekar; Surya V Seshan
Journal:  J Am Soc Nephrol       Date:  2017-12-26       Impact factor: 10.121

7.  Host alloreactive memory T cells influence tolerance to kidney allografts in nonhuman primates.

Authors:  Ognjenka Nadazdin; Svjetlan Boskovic; Toru Murakami; Georges Tocco; Rex-Neal Smith; Robert B Colvin; David H Sachs; James Allan; Joren C Madsen; Tatsuo Kawai; A Benedict Cosimi; Gilles Benichou
Journal:  Sci Transl Med       Date:  2011-06-08       Impact factor: 17.956

8.  Treatment of acute kidney allograft rejection with a non-mitogenic CD3 antibody.

Authors:  R T Meijer; S Surachno; S L Yong; F J Bemelman; S Florquin; I J M Ten Berge; P T A Schellekens
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

9.  The evolution of the Banff classification schema for diagnosing renal allograft rejection and its implications for clinicians.

Authors:  D M Bhowmik; A K Dinda; P Mahanta; S K Agarwal
Journal:  Indian J Nephrol       Date:  2010-01

10.  Endothelial activation, lymphangiogenesis, and humoral rejection of kidney transplants.

Authors:  Sharon Phillips; Meghan Kapp; Deborah Crowe; Jorge Garces; Agnes B Fogo; Giovanna A Giannico
Journal:  Hum Pathol       Date:  2016-01-14       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.